Carter T. Fields
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Peptidase Inhibition and Analysis
Most-Cited Works
- → Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941(2009)825 cited
- → Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1(1998)383 cited
- → A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies(2011)333 cited
- → Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy(2013)194 cited
- → Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer(2015)180 cited
- → American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12(1998)138 cited
- → A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually High Selectivity against Aurora B(2009)81 cited
- → A Pentacyclic Aurora Kinase Inhibitor (AKI-001) with High in Vivo Potency and Oral Bioavailability(2008)58 cited
- → The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results(2024)38 cited
- → Pharmacokinetics of a novel closantel/ivermectin injection in cattle(2006)24 cited